-
Company Insights
New![]()
Innovation and Patenting activity of NH Foods Ltd Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of NH Foods Ltd Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Insights
New![]()
Innovation and Patenting activity of NH Investment & Securities Co Ltd Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of NH Investment & Securities Co Ltd Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The...
-
Company Profile
![]()
NH Foods Ltd – Company Profile
NH Foods Ltd (NH Foods) is a manufacturer and marketer of food products. The company offers cooked foods, fresh meat and processed meat such as hams and sausages, pre-prepared foods, pork, chicken, and other meat products, retort-packed food, processed marine products and dairy products. NH Foods through Nipponham is involved in farming and breeding of livestocks, such as cattle, hogs, and poultry. The company markets food under Chuka Meisai, Ishigama Kobo and Schau Essen brand names. It sells its products...
Add to Basket -
Product Insights
New![]()
South Field Energy Generation Facility
South Field Energy Generation Facility is a thermal project located in Ohio, United States. The project is owned by Bechtel Corp; ENEOS Holdings Inc; Kyushu Electric Power Co Inc; NH-Amundi Asset Management Co Ltd; Shikoku Electric Power Co Inc and was developed by South Field Energy LLC. The project came online in 2021. Empower your strategies with our South Field Energy Generation Facility report and make more profitable business decisions. Note: This is an on-demand report that will be delivered...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Kidney Cancer (Renal Cell Cancer)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Kidney Cancer (Renal Cell Cancer) Drug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Urinary Tract Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Urinary Tract Cancer Drug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Oropharyngeal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Oropharyngeal Cancer Drug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Bile Duct Cancer (Cholangiocarcinoma)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Kaposi Sarcoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Kaposi Sarcoma Drug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Vaginal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Vaginal Cancer Drug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Colorectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Colorectal Cancer Drug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Non-Small Cell Lung Cancer Drug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Mesenchymal Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Mesenchymal Tumor Drug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Vulvar Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Vulvar Cancer Drug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Pancreatic Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Pancreatic Cancer Drug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Solid Tumor Drug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Lung Cancer Drug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Anal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Anal Cancer Drug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Human Papillomavirus (HPV) Associated Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Human Papillomavirus (HPV) Associated Cancer Drug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Metastatic Colorectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Metastatic Colorectal Cancer Drug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for the treatment...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.